Seizures Are Not Epilepsy: The Critical Window Between Autoimmune Encephalitis and an Irreversible Diagnosis

Autoimmune Neurology Series

Why early autoantibody testing is the single most important intervention before a treatable inflammatory seizure disorder becomes a lifelong epilepsy — and why India needs a 21-marker panel to find every patient who can still be helped.

ZeiniX Life Sciences | Autoimmune Neurology Diagnostics | India

Expert Perspective

In 2017, the International League Against Epilepsy (ILAE) formally recognised autoimmune aetiology as one of six distinct causes of epilepsy. It was an overdue acknowledgment of a biological reality that clinicians treating refractory seizure disorders had suspected for years: that in a meaningful proportion of patients with seizures that resist antiepileptic drugs, the brain is not epileptic — it is inflamed. The enemy is not aberrant neural circuitry but an immune system that has turned against its own nervous tissue.

Yet this recognition has introduced a terminology problem with real clinical consequences. The phrase “autoimmune epilepsy” has entered wide usage, often applied to patients who do not yet have epilepsy at all — but may develop it if treatment is delayed. Understanding where autoimmune encephalitis ends and autoimmune epilepsy begins is not a semantic exercise. It is the clinical question on which a patient’s entire prognosis depends.

Most autoimmune encephalitides present with seizures, but the probability of evolving to epilepsy is relatively small. The risk is far greater when diagnosis is delayed and the inflammatory window is allowed to close

The Spectrum: From Inflammation to Epileptogenesis

Autoimmune encephalitis (AE) and autoimmune epilepsy occupy opposite ends of a clinical continuum — and the distance between them is measured, critically, in time. At the early end of this spectrum, seizures are acute symptomatic events: direct, reversible consequences of ongoing neuroinflammation mediated by autoantibodies against neuronal surface antigens. Remove the immune trigger through targeted immunotherapy and the seizures, in most cases, will resolve. The brain has not yet been structurally remodelled. The epileptogenic transformation has not occurred.

At the later end of the spectrum sits true autoimmune-associated epilepsy — a state where the brain has acquired an enduring propensity to generate seizures, not because the inflammation is still active, but because structural damage has been inflicted, often irreversibly, during the period of untreated or inadequately treated encephalitis. These patients require lifelong antiseizure medication. They are no longer treatable with immunotherapy alone. The biological clock ran out.

Acute Symptomatic Seizures

Fully reversible

Active Encephalitis with Seizures

Paranodal neurofascin

Persistent Seizures, Partial Response

Nodal neurofascin

Structural Change, Refractory Seizures

Paranodal adhesion

Autoimmune-Associated Epilepsy

Contactin-associated

The transition from one end of this spectrum to the other is not inevitable. It is, in most cases, preventable — provided the underlying autoimmune aetiology is identified early enough for immunotherapy to interrupt the epileptogenic process before it becomes self-sustaining.

~20%

Of refractory epilepsy of unknown aetiology has an immune basis

~4%

Positive autoantibody rate in unselected epilepsy patients

30%

Of epilepsy patients fail seizure control with antiepileptic drugs alone

Surface Antibodies vs. Intracellular Antibodies: Why the Distinction Defines Prognosis

Not all autoimmune seizure disorders carry the same prognosis — and the most important determinant of reversibility is whether the causal autoantibody targets a neuronal surface antigen or an intracellular protein. This biological distinction has direct clinical implications that every ordering clinician needs to understand.

Autoantibodies directed against cell-surface antigens — such as NMDAR, LGI1, CASPR2, AMPA receptors, and GABA receptors — act primarily by binding to and internalising their target proteins. This causes receptor downregulation and synaptic dysfunction, which drives hyperexcitability and seizures. Crucially, this process is reversible: when antibody titres are reduced through immunotherapy, receptor expression is restored and neuronal function recovers. These patients, when diagnosed early, can achieve seizure freedom without lifelong antiseizure medication.

Autoantibodies against intracellular targets — including ANNA-1 (anti-Hu), ANNA-2 (anti-Ri), PCA-1 (anti-Yo), Amphiphysin, and CRMP-5 — tell a different story. These are typically markers of a T-cell mediated cytotoxic process, frequently paraneoplastic in origin. By the time seizures develop, irreversible neuronal damage has often already occurred. The prognosis for seizure freedom is considerably poorer, and the priority shifts to tumour detection and suppression of ongoing autoimmunity rather than reversal of synaptic dysfunction.

Neuronal Surface Antibodies

Surface Antigen — Synaptic & Ion Channel Targets

These antibodies act by binding to and internalising their target receptors, causing reversible synaptic dysfunction and hyperexcitability. When diagnosed early, seizures typically resolve with immunotherapy without the need for lifelong antiseizure medication. The ZeiniX panel covers a broad range of validated surface antigens — including several that are absent from routine commercial panels available in India.

High reversibility when diagnosed early

Voltage-Gated Channel Complex Antibodies

A clinically important subset of surface antibodies targeting proteins within the voltage-gated potassium channel complex. Associated with limbic encephalitis, faciobrachial dystonic seizures, and Morvan syndrome. Respond well to early corticosteroid and immunotherapy treatment, with excellent long-term cognitive outcomes when intervention precedes full encephalitis.

High reversibility with prompt treatment

Inhibitory Receptor Antibodies

Surface Antigen — GABAergic Targets

Antibodies targeting inhibitory neurotransmitter receptors drive profound cortical and limbic hyperexcitability. May present as refractory status epilepticus. Identifying these antibodies directs immunotherapy and — where relevant — triggers urgent search for an underlying malignancy. Missed without dedicated, broad-spectrum surface antibody testing.

Partial reversibility — early treatment critical

Paraneoplastic / Intracellular Antibodies

Intracellular Antigen — T-Cell Mediated

Reflect cytotoxic T-cell mediated neuronal injury, frequently in the context of an occult malignancy. Structural damage is often established at the time of diagnosis. The primary clinical value is as a tumour biomarker: identification mandates urgent oncological investigation. The ZeiniX panel covers a comprehensive range of paraneoplastic antibodies, including rare markers unavailable in routine laboratory settings.

Low reversibility — tumour search is priority

Glial Markers

Glial Antigen — Astrocytic Targets

Antibodies targeting astrocytic proteins cause autoimmune meningoencephalitis, often with a relapsing course that closely mimics viral or demyelinating disease. Seizures are present in a subset. Steroid-responsive and frequently misdiagnosed without dedicated glial marker testing. Inclusion in a comprehensive panel significantly reduces misdiagnosis in this treatable population.

High reversibility with corticosteroids

The critical implication
Seizures in a patient with a pathogenic neuronal surface antibody are not epilepsy — they are acute symptomatic events that will resolve with immunotherapy if treatment is initiated promptly. Labelling these patients as having epilepsy and loading them with antiseizure medications is not only inadequate — it delays the life-altering intervention they actually need. The antibody test is what makes this distinction possible.

The Faciobrachial Dystonic Seizure: A Case Study in Why Minutes — and Markers — Matter

Perhaps no clinical observation in autoimmune neurology makes the case for early diagnosis more vividly than the faciobrachial dystonic seizure (FBDS) in LGI1 antibody encephalitis. These brief, frequent seizures — involving unilateral facial and arm dystonic posturing, occurring up to hundreds of times per day — are pathognomonic of anti-LGI1 disease. They do not respond to conventional antiepileptic drugs. But they respond rapidly and completely to immunotherapy.

Crucially, multiple studies have demonstrated that patients who receive immunotherapy at the FBDS stage — before full limbic encephalitis develops — have significantly better cognitive outcomes than those treated after the encephalitic syndrome is established. FBDS is not yet limbic encephalitis. It is the warning shot. The patient standing at the FBDS stage is still standing in the reversible zone. Every week of diagnostic delay pushes them further into irreversibility.

The LGI1 antibody is one marker among twenty-one in the ZeiniX panel. Without it — or without a panel broad enough to test for it — this patient receives a diagnosis of cryptogenic focal epilepsy, an antiepileptic drug prescription, and a follow-up appointment. They do not receive immunotherapy. The window closes quietly.

The ZeiniX 21-Marker Autoimmune Epilepsy Panel: Comprehensive by Design

ZeiniX Life Sciences offers India’s most comprehensive validated autoantibody panel for the evaluation of suspected autoimmune encephalitis and autoimmune epilepsy. The panel was not assembled from commercially available reagent kits. It was built, validated, and refined at the intersection of clinical autoimmune neurology and advanced diagnostic immunology — in collaboration with a Centre of Excellence that processes and validates every result against confirmed positive controls.

ZeiniX Autoimmune Epilepsy Panel — 21 Markers

Covering the full antigenic spectrum across three functional categories — each targeting a distinct mechanism of immune-mediated neurological injury — alongside a critical provision for antibodies that escape conventional testing entirely.

The complete 21-marker composition is proprietary and available on request from your ZeiniX representative. Panel design reflects India-validated clinical experience and is not replicated by any other laboratory in the country.

The Unclassified Neuronal Antibody: Why the Twenty-First Marker May Be the Most Important

The majority of markers in the ZeiniX panel have defined molecular targets — validated against known antigens, with established clinical correlates and published literature. They are the foundation of evidence-based autoimmune neurology. But the provision for Unclassified Neuronal Antibodies is in many ways the most consequential element of the panel, and it deserves specific attention.

Autoimmune encephalitis is not a closed classification. The field continues to discover new pathogenic antibodies, and the pace of discovery has accelerated dramatically over the past fifteen years. Many patients who present today with a clinical syndrome consistent with autoimmune encephalitis — subacute onset, psychiatric features, seizures, CSF pleocytosis, MRI changes — will test negative on every named marker in a standard panel. The response in a routine laboratory is to report all results as negative and return the panel. The patient is left without a diagnosis.

A negative result on a fixed panel is not the same as a negative result. It means the antibody was not among those tested. In autoimmune neurology, what is not tested can still be killing neurons.

The ZeiniX approach is different. When a sample is seropositive for a neuronal antibody that does not match any of the characterised markers in the panel, our laboratory does not discard the signal. It is reported as an Unclassified Neuronal Antibody — with documentation of the pattern of neuronal binding observed, the substrate used, and the clinical context. This result is meaningful. It tells the treating neurologist that an antibody-mediated process is occurring. It supports a clinical decision to initiate immunotherapy. It may, over time, as the case is followed and the literature evolves, be reclassified against a newly described antigen.

ZeiniX and Amrita Institute of Medical Sciences: A Centre of Excellence for Unclassified Antibodies

The ability to meaningfully identify and interpret unclassified neuronal antibodies is not a capability that can be established by sourcing a commercial kit. It requires a substrate with broad neuronal antigen expression, experienced laboratory scientists who can distinguish genuine neuronal binding patterns from non-specific signals, and — critically — a clinical partner capable of correlating serological findings with detailed patient phenotypes.

Centre of Excellence

ZeiniX Life Sciences and the Neuro-Immunology Laboratory at the Department of Neurology, Amrita Institute of Medical Sciences, Cochin, function as an integrated Centre of Excellence for autoimmune neurology diagnostics in India. All samples from the ZeiniX Autoimmune Epilepsy Panel are tested and validated at Amrita — one of India’s foremost academic neurology centres with dedicated clinical and research expertise in autoimmune brain disorders.

This partnership means that an unclassified neuronal antibody result is not generated in a diagnostic vacuum. It emerges from a setting where the laboratory scientist, the clinical neurologist, and the diagnostic report exist in active dialogue — the only environment in which such findings can be responsibly interpreted and acted upon. For patients with treatment-resistant seizures and a clinical syndrome consistent with autoimmune encephalitis, this infrastructure may be the difference between a diagnosis and a decade of empirical treatment.

What the Diagnostic Delay Looks Like in Practice

The literature on diagnostic delay in autoimmune encephalitis is sobering. Patients with NMDAR antibody encephalitis frequently spend weeks to months in psychiatric wards before the autoimmune aetiology is recognised — a period during which irreversible neuronal injury accumulates. Patients with certain voltage-gated channel complex antibody disorders are often treated through multiple antiepileptic drug trials before pathognomonic seizure semiology is correctly linked to an immune cause. Patients with paraneoplastic antibody-associated encephalitis have their underlying malignancy discovered only after the neurological syndrome has progressed — losing the early treatment window for both conditions simultaneously.

In India, where access to specialised autoimmune neurology workup is geographically and economically variable, the diagnostic journey is longer still. Patients with new-onset refractory status epilepticus (NORSE) — a presentation where autoimmune aetiology accounts for a significant proportion of cases and where early immunotherapy can be lifesaving — are managed for days or weeks as cryptogenic, with escalating antiepileptic drug regimens and intensive care resources, while the underlying inflammatory process continues unchecked.

When Should Autoimmune Epilepsy Testing Be Ordered?

The clinical triggers for autoimmune antibody evaluation in a patient with seizures are well-described in the literature and should be part of the reflex workup in any of the following scenarios:

Clinical triggers for the ZeiniX Autoimmune Epilepsy Panel

New-onset seizures with subacute progression, particularly in the absence of a structural lesion on MRI or a clear metabolic cause.

Seizures with psychiatric or cognitive features disproportionate to the seizure burden alone — behavioural change, memory impairment, altered consciousness, or psychosis in temporal proximity to seizure onset.

Faciobrachial dystonic seizures or other brief, stereotyped, high-frequency seizure patterns not explained by conventional epilepsy diagnoses.

New-onset refractory status epilepticus (NORSE) without a clear infectious or metabolic aetiology.

The clinical triggers for autoimmune antibody evaluation in a patient with seizures are well-described in the literature and should be part of the reflex workup in any of the following scenarios:

Seizures in a patient with a known or suspected underlying malignancy, or with clinical features suggesting paraneoplastic syndrome.

Seizures resistant to two or more appropriate antiepileptic drug regimens in a patient who has not undergone comprehensive autoimmune evaluation.

CSF pleocytosis in a patient with seizures, in the absence of infectious encephalitis.

Conclusion: The Inflammatory Window Is Real — and It Closes

Autoimmune encephalitis is a disease that tests the medical system’s capacity to act in time. The seizures that bring patients to neurological attention in the early phase of anti-NMDAR encephalitis, LGI1 disease, GABA-B encephalitis, or DPPX-associated hyperexcitability are not epilepsy. They are the brain’s distress signal from an ongoing immune attack. The immune attack can be stopped. The seizures can be resolved. The brain can recover — if the antibody is identified, the immunotherapy is initiated, and the inflammatory window is used before it closes.

Once the window closes — once structural damage has accumulated, once the hippocampus has undergone volume loss, once the cortical networks have reorganised around a seizure focus — the patient has epilepsy. Not autoimmune encephalitis with seizures. Epilepsy. Antiseizure medications for life. No immunotherapy reversal. No return to baseline.

The ZeiniX 21-marker Autoimmune Epilepsy Panel, validated at the Centre of Excellence at Amrita Institute of Medical Sciences, Cochin, exists because this distinction matters profoundly — and because finding every antibody-positive patient, including those with antibodies that no commercial kit yet names, is the only way to ensure that those patients get the treatment that can still help them.

Early testing is not a clinical luxury. In autoimmune epilepsy, it is the intervention.

REFERENCES :

Dubey D et al. Autoimmune Epilepsy. Semin Neurol. 2019;39(2):261–270. PMID: 31240596
Bien CG et al. Autoimmune encephalitis-associated epilepsy. Nat Rev Neurol. 2025. PMID: 40316743
Steriade C et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions. Epilepsia. 2020;61(7):1341–1351. PMID: 30714986
Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med. 2018;378(9):840–851. PMID: 26060904
Scheffer IE et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–521. PMID: 27112680
Irani SR et al. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900. PMID: 26626229